CLX

Business profile & competitive position

The Clorox Company operates in the Consumer Defensive sector, specifically the Household & Personal Products industry. That classification means Clorox is a branded staples business: disinfecting and cleaning products, water filtration, cat litter, food items, natural personal care, and, since the GOJO acquisition, professional hand-hygiene products. The portfolio is meant to generate recurring demand through branded household goods rather than discretionary purchases.

The financial signals, however, complicate any easy "wide-moat" story. The company posts an 8.7% net margin, which is decent for a packaged-goods operator but not an especially high-margin profile. More striking is the return on equity of -1,893.5%. A negative ROE of that magnitude is not driven by operating losses; the recent quarters are profitable, including the August 2026 report of $1.66 EPS versus a $1.64 estimate. Instead, a deeply negative ROE almost always reflects a shrunken or negative equity base, frequently the result of leverage, shareholder deficits, buyback programs, or acquisition-related accounting. For Clorox, that means the balance sheet structure—not the brand economics—is what makes ROE look alarming. The 8.7% net margin is the cleaner signal of underlying profitability, and it points to a competitive position that is solid but not dominant on a pure margin basis.

Financial posture

As of the snapshot date, Clorox carries a $12.9 billion market cap and trades at 22.1 times earnings. For a low-volatility Consumer Defensive name, that is a full but not extreme valuation. The beta of 0.53 confirms the stock is far less sensitive to broad market swings than the average equity, consistent with the staples industry's defensive reputation. The current price of $106.62 sits well above the 50-day exponential moving average of $98.24, while the RSI reads 66.5—close to traditionally overbought territory.

Against that backdrop, the negative ROE again matters structurally rather than operationally. It tells an analyst that book equity has been compressed, likely through debt-funded returns to shareholders or acquisitions, so leverage is a meaningful part of the total return story. The 8.7% net margin suggests the core business still converts sales into profits at a fairly normal packaged-goods rate. Investors evaluating Clorox therefore have to weigh the stability of demand against the leverage embedded in the capital structure and the 22.1x earnings multiple.

Macro & geopolitical exposure

Because Clorox sits in Household & Personal Products, its headline risk is tied to input costs, logistics, regulation, and consumer behavior rather than deep cyclicality. The most direct macro exposure is raw-material inflation: resins, chemicals, fragrances, paper-based packaging, agricultural commodities, and energy all feed into cleaning, litter, and food products. Freight and distribution costs also move the model, because bulky household goods are expensive to move. On the regulatory side, disinfectant claims, EPA registrations, ingredient disclosure, consumer-product safety rules, and FTC advertising scrutiny create compliance risk specific to this industry. Currency matters to the extent products are sold abroad, and tariffs or trade policy can affect both imported inputs and finished goods. Finally, staples producers face persistent private-label competition, which tends to accelerate when consumers feel pressure from inflation or higher interest rates.

Recent developments

Clorox's most recent news cycle centers on its fiscal fourth-quarter 2026 results. On August 3, 2026, the company reported actual EPS of $1.66 against an estimate of $1.64, a 1.2% beat. The market responded quickly: the stock rose 6.52% the next trading day and finished the following five sessions up 8.45%. Coverage from zacks.com on August 4 flagged that both earnings and sales topped estimates, with GOJO contributing to sales momentum. The same day, zacks.com reported that management's earnings call highlighted inflation as a headwind but also described share recovery as building. That sets up the key tension: top-line performance is improving, but cost pressures remain. Also on August 4, benzinga.com noted that several analysts raised their forecasts following the better-than-expected quarter, which can influence the unofficial consensus heading into the next reporting period. On August 6, zacks.com published a valuation comparison, "NWL vs. CLX: Which Stock Is the Better Value Option?"—a reminder that investors are actively weighing Clorox against other consumer-staples names rather than treating the stock in isolation.

Earnings behavior & post-earnings drift

Clorox has beaten earnings estimates in 6 of the last 8 reported quarters, a 75% beat rate, with an average earnings surprise of 9.4%. Across those quarters, the average 5-day price move after the report has been 1.38%, classified as a drift to the upside. That said, the average masks considerable volatility and inconsistency between the immediate reaction and the multi-day drift.

The most recent quarter, reported August 3, 2026, is the clearest post-earnings winner: a modest 1.2% beat drove a 6.52% one-day gain and an 8.45% five-day gain. The quarter before, on April 30, 2026, Clorox beat by a larger 5.8% ($1.64 actual versus $1.55 estimated) yet the stock fell 9.67% the next day and was down 4.49% five days later. On February 3, 2026, the company missed by 2.8% ($1.39 versus $1.43), but the stock rose 2.43% the next day and 5.63% over the following week. The November 3, 2025 quarter showed a 3.9% beat ($0.85 versus $0.818) with only a 1.17% next-day gain and a -4.08% five-day drift.

The takeaway is that beating the estimate has been the base case, but the market's reaction depends heavily on guidance, margin commentary, and comparable expectations embedded in the price at the time of the report. With the next earnings scheduled for November 3, 2026 after the close and the consensus EPS estimate at $1.07, traders will be watching whether the August beat-streak momentum continues and whether management's inflation messaging has improved.

For a deeper dive into how these factors are shaping the bull and bear cases, readers should review the full institutional verdict, including the latest analyst rating changes, estimate revisions, and consensus positioning around Clorox's upcoming November 2026 report.